paper author researcher Christina Burgi, He said that in order to achieve the goal of ending infections by 2030, a series of obstacles need to be overcome, such as the detection of undiagnosed infections, the capture of lost cases, initiation and compliance.Treat and prevent new viral infections Hepatitis C (Hepatitis C virus). Both Navarre’s health care capacity and the availability of drugs make this achievable, but to do so “it will be necessary to restore a more rigorous pace of diagnosis and treatment of active infections,” Bourgi said.
The second approach evaluated an intervention proposed by the Ministry of Health that recruited patients with an incomplete diagnosis of HCV to complete the diagnosis and referred those who were diagnosed for drug treatment. A review of old laboratory results revealed that 281 patients had underdiagnosed HCV infection without good treatment options.
Navarre on track to eliminate hepatitis C infection by 2030
As of the time of this assessment, 67% had been contacted. Of these, 28% had an active infection and were referred for treatment, 40% had false positives, and 31% of infections resolved on their own. “This intervention is very effective and very enriching on a personal and professional level because it allows people who don’t know they have the virus to be diagnosed with an active infection, preventing their progression over time. Progression to severe stages such as cirrhosis and hepatocellular carcinoma. Cristina Burgi points out. “Coordination and close collaboration between different health professions has allowed us to maintain good rates of diagnosis and treatment of HCV infection, which is in part affected by HCV infection. COVID-19 Pandemic‘, he concluded.
The third approach assessed the effectiveness of direct-acting antiviral therapy initiated between 2015 and 2020 at the University Hospital of Navarra and followed until 2021 to examine how many cases achieved a sustained viral response, ie cure. infection. Of the 1,366 patients who started treatment, 19 percent were also infected with human immunodeficiency virus (HIV). This sustained viral response was achieved in 96.6% of patients who initiated treatment and in 97.7% of patients who completed follow-up. After repeating the treatment for patients who failed the first time, the cure rate reached 100%. The drugs showed a good safety profile, as only three of the total number of patients treated had to change treatment due to adverse effects. The paper concludes that, if this goal is prioritized, current diagnostic and therapeutic means can eliminate HCV infection in well-organized healthcare settings.